News Results
There are 463,764 News Results
Nov 1, 2024
2024 Ongoing Earnings Guidance Narrowed -- 2024 third quarter GAAP earnings of $1.45 per diluted share -- 2024 third quarter ongoing earnings of $1.43 per diluted share -- Narrowed 2024...
Nov 1, 2024
INDIANAPOLIS, Nov. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader...
Nov 4, 2024
BETHESDA, Md., Nov. 4, 2024 /PRNewswire/ -- Centrus Energy Corp. (NYSE American: LEU) ("Centrus") today announced its intention to offer, subject to market conditions and other factors, $350 million aggregate...
Nov 5, 2024
BETHESDA, Md. , Nov. 5, 2024 /PRNewswire/ -- Centrus Energy Corp. (NYSE American: LEU) ("Centrus") today announced the pricing of $350 million aggregate principal amount of 2.25% Convertible Senior Notes...
Nov 6, 2024
ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs...
Nov 7, 2024
Park-Ohio Holdings Corp. (NASDAQ: PKOH) today announced its results for the third quarter of 2024. “We are pleased with the performance of our Company during the third quarter. While demand...
Nov 7, 2024
Cadre Holdings, Inc. (NYSE: CDRE) (“Cadre” or “Company”), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military...
Nov 7, 2024
Allient Inc. (Nasdaq: ALNT) (“Allient” or the “Company”), a global designer and manufacturer of precision and specialty Motion, Controls and Power products and solutions for targeted industries and applications, today...
Nov 6, 2024
-- Advancement in Phase I/II AFFINITY DUCHENNE(®) trial of RGX-202 for Duchenne Muscular Dystrophy; pivotal trial initiation and first functional data expected this month -- BLA submission for RGX-121 initiated...
Nov 6, 2024
-- Revenues for the quarter ended September 30, 2024 total $3.8 billion, pretax loss is $5 million, and net loss is $43 million -- Adjusted EBITDA is $557 million, adjusted...
